Biological therapy update in colorectal cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 4, 2007, Pages 509-519

  Sorscher, Steven M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bevacizumab; Cetuximab; Chemotherapy; Colon cancer; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; MONOCLONAL ANTIBODY DC101; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN; VATALANIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; PHTHALAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ACNE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANAPHYLAXIS; ARTERY EMBOLISM; ARTERY THROMBOSIS; BIOLOGICAL THERAPY; BLEEDING; BONE MARROW TOXICITY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DYSPNEA; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; POSTOPERATIVE HEMORRHAGE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RECTUM CANCER; REVIEW; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION; COLORECTAL TUMOR; DRUG ANTAGONISM; EXPERT WITNESS; METHODOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL THERAPY; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; EXPERT TESTIMONY; FLUOROURACIL; HUMANS; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34047143802     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.4.509     Document Type: Review

References (74)

1. BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3(6):401-410.
2. HATTORI K, DIAS S, HEISSIG B et al.: Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. (2001) 193(9):1005-1014.
3. HATTORI K, HEISSIG B, WU Y et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment. Nat. Med. (2002) 8(8):841-849.
4. FERRARA N: VEGF and the quest for turnout angiogenesis factors. Nat. Rev. Cancer (2002) 2(10):795-803.
5. DOR Y, PORAT R, KESHET E: Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol. Cell Physiol. (2001) 280(6):C1367-C1374.
6. ROBERTS W, PALADE G: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. (1995) 108(6):2369-2379. • Effect of antiangiogenesis on endothelial function.
7. JAIN RK: Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. (2001) 7(9):987-989. • Study of the effects of antiangiogenesis on vascular function.
8. JAIN RK: Barriers to drug delivery in solid tumors. Sci. Am. (1994) 271:58-65.
9. FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3(5):391-400. •• A comprehensive review of bevacizumab.
10. LEE J, CHOW N, WANG S, HUANG S: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer (2000) 36(6):748-753.
11. CHOI HJ, HYUN MS, JUNG GJ, KIM SS, HONG SH: Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology (1998) 55(6):575-581.
12. TAKAHASHI Y, KITADAI Y, BUCANA C, CLEARY K, ELLIS L: Expression of vascular endothelial growth factor and its teceptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. (1995) 55(18):3964-3968.
13. WILLETT CG, BOUCHER Y, DI TOMASO E et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. (2004) 10(2):145-147.
14. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350(23):2335-2342. •• Landmark study showing improved survival with bevacizumab therapy combined with chemorherapy compared with chemotherapy alone.
15. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ: The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an updated interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA (22-24 January 2004).
16. REDDY GK: The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin. Colorectal Cancer (2005) 4(5):300-301.
17. GIANTONIO BJ, CATALANO PJ, MEROPOL NJ et al.: High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study 3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL, USA (27-29 January 2005).
18. GIANTONIO BJ, CATALANO PJ, O'DWYER PJ, MEROPOL NJ, BENSON AB III: Impact of bevacizumab dose reduction on clinical outcomes for patients treated on the Eastern Cooperative Oncology Group's Study E3200. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. San Francisco, CA, USA (26-28 January 2006).
19. EMMANOUILIDES C, PEGRAM M, ROBINSON R et al.: Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. Tech. Coloproctol. (2004) 8:s50-s52.
20. SALTZ LB, LENZ H-J, HOCHSTER H et al.: Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13-17 May 2005).
21. FUCHS C, MARSHALL J, MITCHELL E et al.: A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006). •• Study demonstrating that bevacizumab-containing regimens show improved response compared with those without bevacizumab.
22. HOCHSTER HS, HART LL, RAMANATHAN RK et al.: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
23. CASSIDY J, CLARKE S, RUBIO ED et al.: First efficacy and safety results from XELOX-1/NO16968, a randomized 2x2 factorial Phase III trial of XELOX versus FOLFOX4+ bevacizumab or placebo in first-line metastatic colorectal cancer (MCRC). Abstract Book of the 31st ESMO Congress. Istanbul, Turkey (29 September - 3 October 2006).
24. BERRY SR, CUNNINGHAM D, MICHAEL M et al.: Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-First B.E.A. Trial. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
25. HEDRICK E, KOZLOFF M, HAINSWORTH J et al.: Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
26. SALTZ LB, CHUNG KY, TIMONEY J, PARK V, HOLLYWOOD E: Simplification of bevacizumab (bev) administration: do we need 90, 60, or even 30 minute infusion times? American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
27. TAKAHASHI Y, TUCKER SL, KITADAI Y et al.: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. (1997) 132(5):541-546.
28. ISHIGAMI SI, ARII S, FURUTANI M et al.: Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer (1998) 78(10):1379-1384.
29. WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95(4):1789-1797.
30. AMAYA H, TANIGAWA N, LU C et al.: Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett. (1997) 119(2):227-235.
31. DIAZ-RUBIO E, SCHMOLL HJ: The future development of bevacizumab in colorectal cancer. Oncology (Huntington) (2005) 69(Suppl. 3):34-45.
32. STEWARD WP, THOMAS A, MORGAN B et al.: Expanded Phase I/II study of PTK787/ZK 222584(PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5-8 June 2004).
33. SCHLEUCHER N, TRARBACH T, JUNKER U et al.: Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5-8 June 2004).
34. THOMAS A, MORGAN B, DREVS J et al.: Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 Phase I studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. American Society of Clinical Oncology Annual Meeting. San Francisco, CA, USA (12-15 May 2001).
35. HECHT JR, TRARBACH T, JAEGER E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13-17 May 2005).
36. TYAGI P: Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin. Colorectal Cancer (2005) 5(1):24-26.
37. KOEHNE C, BAJETTA E, LIN E et al.: Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584(PTK/ZK) or placebo (CONFIRM 2). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
38. MAINDRAULT-GOEBEL F, LLEDO G, CHIBAUDEL B et al.: OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
39. BASELGA J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 7:2-8.
40. BASELGA J, ALBANELL J: Epithelial growth factor receptor interacting agents. Hematol. Oncol. Clin. North Am. (2002) 16(5):1041-1063.
41. SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. (1995) 19(3):183-232.
42. MAYER A, TAKIMOTO M, FRITZ E et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 71(8):2454- 2460.
43. SATO JD, KAWAMOTO T, LE AD et al.: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. (1983) 1:511-529.
44. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. (2003) 21(14):2787-2799. •• Comprehensive review of EGFR antagonists.
45. CUNNINGHAM D, HUMBLET Y, SIENA S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl J. Med. (2004) 351(4):337-345. •• Clinical trial demonstrating a role for cetuximab in combination with irinotecan after tumor progression on irinotecan.
46. ALEKSHUN T, GARRETT C: Targeted therapies in the treatment of colorectal cancers. Cancer Control (2005) 12(2):105-110.
47. SALTZ LB, RUBIN M, HOCHSTER HS et al.: Acne-like rash predicts response in patients treated with cetuximab (IMC-225) plus irinotecan (CPT-11) in CPT-11 refractory colorectal cancer that expresses EGFR. J. Clin. Invest. (2001) 68:559.
48. SALTZ LB, RUBIN M, HOCHSTER HS et al.: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). American Society of Clinical Oncology Annual Meeting. San Francisco, CA, USA (12-15 May 2001).
49. VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) {+/-} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006). •• This trial demonstrates that cetuximab improves response rates with chemotherapy compared with chemotherapy alone.
50. VINCENZI B, SANTINI D, RABITTI C et al.: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre Phase II trial. Br. J. Cancer (2006) 94(6):792-797.
51. SOBRERO A, SCHEITHAUER W, MAUREL J et al.: Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): safety analysis of the first 400 patients in a randomized Phase III trial (EPIC). American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA (13-17 May 2005).
52. ROUGIER P, RAOUL J-L, VAN LAETHEM J-L et al.: Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5-8 June 2004).
53. BALIN-GAUTHIER D, DELORD JP, ROCHAIX P et al.: In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal rumor cell lines expressing different level of EGFR. Cancer Chemother. Pharmacol. (2006) 57(6):709-718.
54. BADARINATH S, MITCHELL EP, JENNIS A et al.: Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary safety analysis of a randomized Phase III trial. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5-8 June 2004).
55. CHUNG KY, SHIA J, KEMENY NE et al.: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. (2005) 23(9):1803-1810.
56. TONRA JR, DEEVI DS, CORCORAN E et al.: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targered therapy. Clin. Cancer Res. (2006) 12(7):2197-2207.
57. HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23(11):2544-2555.
58. HERBST RS, MININBERG E, HENDERSON T et al.: Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proleferation with combined bevacizumab and erlotinib hci as targeted cancer therapy in patients with recurrent non-small cell lung cancer. Eur. J. Cancer (2003) 1(5):s293.
59. SELVAGGI G, NOVELLO S, TORRI V et al.: Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann. Oncol. (2004) 15(1):28-32.
60. CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6(9):3739-3747.
61. SHAHEEN RM, AHMAD SA, LIU W et al.: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receprors. Br. J. Cancer (2001) 85(4):584-589.
62. MACKENZIE MJ, HIRTE HW, GLENWOOD G et al.: A Phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tytosine kinase inhibitor, in patients with metastatic colorectal cancer. Invest. New Drugs (2005) 23(2):165-170.
63. CHO CD, FISHER GA, HALSEY J, SIKIC BI: Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest. New Drugs (2006) 24(2):117-123.
64. FOON KA, YANG X-D, WEINER LM et al.: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):984-990.
65. PEETERS M, VAN CUTSEM E, SALVATORE S et al.: A Phase III, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) versus BSC in patients (pts) with metastatic colorectal cancer (mCRC). Proceedings, Annual Meeting of the American Association for Cancer Research. Washington DC, USA (1-5 April 2006).
66. WAINBERG Z, HECHT JR: A Phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin. Colorectal Cancer (2006) 5(5):363-367.
67. HECHT JR, PATNAIK A, MALIK I et al.: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. American Society of Clinical Oncology Annual Meeting. New Orleans, LA, USA (5-8 June 2004).
68. BERLIN J, NEUBAUER M, SWANSON P et al.: Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing > = 10% epidermal growth factor receptor (EGFr). American Society of Clinical Oncology Annual Meeting. Atlanta, GA, USA (2-6 June 2006).
69. WILD R, FAGER K, FLEFLEH C et al.: Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther. (2006) 5(1):104-113.
70. VALLBOHMER D, ZHANG W, GORDON M et al.: Molecular determinants of cetuximab efficacy. J. Clin. Oncol. (2005) 23(15):3536-3544.
71. MORONI M, VERONESE S, BENVENUTI S et al.: Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. (2005) 6(5):279-286.
72. JUBB AM, HURWITZ HI, BAI W et al.: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J. Clin. Oncol. (2006) 24(2):217-227.
73. INCE WL, JUBB AM, HOLDEN SN et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl Cancer Inst. (2005) 97(13):981-989.
74. ULLENHAG GJ, SPENDLOVE I, WATSON NF et al.: A Neoadjuvant/ adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Cancer Res. (2006) 12(24):7389-7396.